Lymphoma Biomarkers - What Does the Evidence Support

Archived study

Combines a small public DLBCL cohort with a focused review of five candidate biomarkers relevant to CD20-by-CD3 bispecific therapy. The cohort contained 48 patients; CD58 and TP53 mutation-positive counts were 3/41 and 5/41 within their profiled denominators. The evidence review covered 13 primary reports, distinguishing biological context, prognosis, monitoring and treatment benefit.

Interpretation and limits

The cohort has no bispecific-treatment response endpoint, and the literature review is not exhaustive. Bulk RNA is not surface protein or a clinical threshold. Prognostic and treated-patient associations do not establish differential treatment benefit or a therapy-selection rule; clinical estimates were checked for transcription, not refitted.

Package and provenance

The unchanged research package comes from the upstream archive. It retains the original conversation and included scientific artifacts, including analysis code, results and figures. The poster is an AI-generated thematic illustration, not study evidence. This introduction summarizes archived findings; the analysis was not rerun. Later bounded checks do not certify the entire study or mean the original package was corrected.

Import provenance

This case was added to the Academic Research category on 2026-10-13, with the archived upstream case recorded as its source. The supplied session export and poster were uploaded without changing their contents. This introduction summarizes the archived findings and was standardized for the repository. The study, external data sources, and scientific results were not rerun or independently reverified for this import.

This GitHub catalog imports the case from the verified Hugging Face snapshot. The session export is referenced through that fixed revision; the cover and introduction are stored in this repository.

Case files

• Session export
• Case poster